Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03182686 · ClinicalTrials.gov registry record · Phase 3

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

A Phase 3 study, sponsored by Ampio Pharmaceuticals..

Completed
Registry status
Phase 3
Development phase
168
Enrollment target

NCT03182686: Completed Phase 3 study, sponsored by Ampio Pharmaceuticals..

NCT03182686 is a Phase 3 study that has completed, run by Ampio Pharmaceuticals.. The registered enrollment target is 168 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03182686, a Phase 3 study, has completed, sponsored by Ampio Pharmaceuticals..

COMPLETED
Registry status
Phase 3
Development phase
168 participants
Enrollment target

Study Summary

This is a phase 3 randomized study to confirm the efficacy of an intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.

Primary Outcome

Using the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria of WOMAC A Pain subscore, WOMAC C Function subscore, and PGA as composite endpoints. A patient in this study will be considered a responder for the purpose of efficacy analysis if the following criteria are met: (1) demonstration of ≥ 50% improvement AND a 1.0-unit change in pain OR 1.0-unit change in function OR If the patient does not meet this criterion, then

Interventions

  • BIOLOGICAL 4 mL injection of Ampion
  • DRUG 4 mL Injection of Placebo

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2017-06-19
Est. Completion 2017-12-07
Phase Phase 3
Ampio Pharmaceuticals.

12 total trials

What the finished NCT03182686 record still lists

NCT03182686 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which 4 mL injection of Ampion is the first listed.

NCT03182686 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03182686 about?

NCT03182686 is a clinical study titled "AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee". This is a phase 3 randomized study to confirm the efficacy of an intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.

What is the current status of trial NCT03182686?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2017-06-19. Estimated completion is 2017-12-07.

What interventions are being tested in trial NCT03182686?

The interventions under investigation include: 4 mL injection of Ampion (BIOLOGICAL), 4 mL Injection of Placebo (DRUG).

Who is sponsoring clinical trial NCT03182686?

This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03182686's enrollment target sits among peer trials

168 1459th of 2000 higher than 538 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

  • NCT03536897 · 168 participants

    IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

  • NCT04078230 · 168 participants · NA

    Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

  • NCT04159168 · 168 participants · NA

    Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03182686, the US trial registry maintained by the National Library of Medicine. NCT03182686 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.